An estimated 40-60% of diabetic patients are at risk for the development of diabetes-related foot complications. Current treatments leave patients at risk for developing infections involving antibiotic-resistant strains of bacteria. Researchers at the University of California, Davis have developed a topical treatment for diabetic wounds.
Diabetes-related foot wounds account for about 20% of all hospitalizations of diabetic patients. These wounds are extremely difficult to manage and result in an estimated 82,000 non-traumatic lower limb amputations each year, or about one amputation every six minutes.
Current topical methods for treating diabetic wounds include debriedment to remove necrotic and infected tissue, dressings to provide a moist wound environment, topical application of antimicrobial or biologic agents, offloading, physical therapy, and education. However, these different treatment modes often fail to achieve complete wound closure since they do not address the main culprit, persistent inflammation. Furthermore, while the use of antibiotics often ameliorates bacterial infection and to some extent inflammation, excessive use can lead to the development of antibiotic-resistant bacterial strains.
Researchers at the University of California, Davis have developed a method for promoting wound healing, wound re-epithelialization, and dermal regeneration of epithelial tissues and cutaneous wounds. This new method involves the application of an extracellular matrix scaffold that has been populated with mesenchymal stem cells pre-conditioned populated with a beta adrenergic receptor antagonist. This novel topical treatment takes advantage of beta adrenergic antagonists to suppress the release of IL-6, thereby decreasing inflammation and stress in an infected area. This shows potential for allowing complete wound closure and decreasing antibiotic treatment times, thereby reducing a patient’s risk of developing antibiotic-resistant bacterial infections.
|United States Of America||Published Application||20160175485||06/23/2016||2014-074|